Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20 year study in a large French teaching hospital, 1983-2002

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 3, 2006, Pages 506-510

  Robert, Jérôme ^a   Bismuth, Roland ^a   Jarlier, Vincent ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Gentamicin; GISA; S. aureus; Teicoplanin; Vancomycin

Indexed keywords

AGAR; GENTAMICIN; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; CONTROLLED STUDY; CORRELATION FUNCTION; FRANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RANDOM SAMPLE; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; FRANCE; GLYCOPEPTIDES; HOSPITALS; HUMANS; METHICILLIN RESISTANCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 32644442192     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki486     Document Type: Article

References (19)

1. Tiemersma EW, Bronzwaer SLAM, Lyytikäinen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis [serial on the Internet] 2004. http://www.cdc.gov/ncidod/EID/vol10no9/04-0069.htm. (6 September 2005, date last accessed).
2. Mainardi JL, Shlaes DM, Goering RV et al. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995; 171: 1646-50.
3. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
4. Fridkin SK, Hageman J, McDougal LK et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-39.
5. Rotun SS, McMath V, Schoonmaker DJ et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147-9.
6. Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: Apocalypse now? Lancet 1997; 350: 1644-5.
7. Cercenado E. Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem? Clin Microbiol Infect 2000; 6: 517-8.
8. Tenover FC, Lancaster MV, Hill BC et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eighth Edition. Susceptibility Tests for Bacteria That Grow Aerobically M02-A8. NCCLS, Wayne, PA, USA.
10. Comité de l'Antibiogramme de la Société Française de Microbiologie. Report 2005. http://www.sfm.asso.fr/doc/download.php?doc= DiU8C&fic=Communique_2005.pdf. (6 September 2005, date last accessed).
11. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001 [Online] Mar-Apr. http://www.cdc.gov/ncidod/eid/vol7no2/tenover.htm (6 September 2005, date last accessed).
12. Denis O, Nonhoff C, Byl B et al. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: Microbiological and clinical features. J Antimicrob Chemother 2002; 50: 383-91.
13. Guerin F, Buu-Hoi A, Mainardi JL et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 2000; 38: 2985-8.
14. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR 2002; 51: 902.
15. Wilson AP, O'Hare MD, Felmingham D, Gruneberg RN. Teicoplanin-resistant coagulase-negative staphylococcus. Lancet 1986; 2: 973.
16. El Solh N, Davi M, Morvan A et al. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides. J Antimicrob Chemother 2003; 52: 691-4.
17. Howe RA, Monk A, Wootton M et al. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis. [Online] 2004 May. http://www.cdc.gov/ncidod/EID/vol10no5/03-0556.htm (6 September 2005, date last accessed).
18. Jarlier V. Bactéries multirésistantes dans les hôpitaux français: Des premiers indicateurs au Réseau d'alerte d'investigation et de surveillance des infections nosocomiales (Raisin). Bull Epid Hebdo [serial on the Internet] 2004; 32-33: 148-151. http://www.invs.sante.fr/beh/2004/32_33/beh_32_33_2004.pdf (6 September 2005, date last accessed).
19. Hubert SK, Mohammed JM, Fridkin SK et al. Glycopeptide-intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999; 37: 3590-3.